PATIENT SELECTION CRITERIA

MITRACLIP THERAPY IS A SAFE, PROVEN, MINIMALLY INVASIVE TREATMENT OPTION FOR:

Patients that have Primary (Degenerative) MR and are considered at prohibitive risk for surgery

PATIENT SHOULD MEET THE FOLLOWING CRITERIA:

1. Significant mitral regurgitation (MR ≥3+)
2. Symptomatic
3. Existing comorbidities do not preclude expected benefit of MR reduction
4. Evaluated by a heart team that includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease
5. Any one of the following prohibitive risk criteria:
   - 30-day STS predicted operative mortality risk score of:
     * ≥ 8% (mitral valve replacement)
     * ≥ 6% (mitral valve repair)
   - Porcelain aorta or extensively calcified ascending aorta
   - Frailty (assessed by in-person cardiac surgeon consultation)
   - Hostile chest
   - Severe liver disease / cirrhosis (MELD Score >12)
   - Severe pulmonary hypertension (systolic pulmonary artery pressure >2/3 systemic pressure)
   - Unusual extenuating circumstance, such as right ventricular dysfunction with severe tricuspid regurgitation, chemotherapy for malignancy, major bleeding diathesis, immobility, AIDS, severe dementia, high risk of aspiration, internal mammary artery at high risk of injury, etc.

Select heart failure patients with Secondary (Functional) MR who remain symptomatic despite GDMT

PATIENT SHOULD MEET THE FOLLOWING CRITERIA:

1. Moderate-to-severe or severe MR (MR ≥ Grade III per American Society of Echocardiography criteria)
2. Symptomatic with MR severity persists despite maximally-tolerated GDMT
3. LVEF ≥ 20% and ≤ 50%
4. LVESD ≤ 70mm
5. Evaluated by a multidisciplinary heart team experienced in the evaluation and treatment of heart failure and mitral valve disease

MitraClip therapy is contraindicated for MR patients with the following conditions:

- Patients who cannot tolerate, including allergy or hypersensitivity to, procedural anticoagulation or post procedural anti-platelet regimen
- Active endocarditis of the mitral valve
- Rheumatic mitral valve disease
- Patients with known hypersensitivity to clip components (nickel / titanium, cobalt, chromium, polyester), or with contrast sensitivity
- Evidence of intracardiac, inferior vena cava (IVC) or femoral venous thrombus

To learn more about the MitraClip therapy or find a center nearest you, visit MitraClip.com/HCP
IMPORTANT SAFETY INFORMATION

MITRACLIP DELIVERY SYSTEMS

INDICATION FOR USE
• The MitraClip™ G4 System is indicated for the percutaneous reduction of significant symptomatic mitral regurgitation (MR ≥ 3+) due to primary abnormality of the mitral apparatus (degenerative MR) in patients who have been determined to be at prohibitive risk for mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, and in whom existing comorbidities would not preclude the expected benefit from reduction of the mitral regurgitation.
• The MitraClip™ G4 System, when used with maximally tolerated guideline-directed medical therapy (GDMT), is indicated for the treatment of symptomatic, moderate-to-severe or severe secondary (or functional) mitral regurgitation (MR; MR ≥ Grade III per American Society of Echocardiography criteria) in patients with a left ventricular ejection fraction (LVEF) ≥ 20% and ≤ 50%, and a left ventricular end systolic dimension (LVESD) ≤ 70 mm whose symptoms and MR severity persist despite maximally tolerated GDMT as determined by a multidisciplinary heart team experienced in the evaluation and treatment of heart failure and mitral valve disease.

CONTRAINDICATIONS
The MitraClip™ G4 System is contraindicated in patients with the following conditions:
• Patients who cannot tolerate, including allergy or hypersensitivity to, procedural anticoagulation or post procedural anti-platelet regimen
• Patients with known hypersensitivity to clip components (nickel / titanium, cobalt, chromium, polyester), or with contrast sensitivity
• Active endocarditis of the mitral valve
• Rheumatic mitral valve disease
• Evidence of intracardiac, inferior vena cava (IVC) or femoral venous thrombosis

WARNINGS
• DO NOT use MitraClip™ outside of the labeled indication.
• The MitraClip™ G4 Implant should be implanted with sterile techniques using fluoroscopy and echocardiography (e.g., transesophageal [TEE] and transthoracic [TTE]) in a facility with on-site cardiac surgery and immediate access to a cardiac operating room.
• Read all instructions carefully. Use universal precautions for biohazards and sharps while handling the MitraClip™ G4 System to avoid user injury. Failure to follow these instructions, warnings and precautions may lead to device damage, user injury or patient injury, including:
  • MitraClip™ Implant erosion, migration or malposition
  • Failure to deliver MitraClip™ G4 Implant to the intended site
  • Difficulty or failure to retrieve MitraClip™ G4 system components

• Use caution when treating patients with hemodynamic instability requiring introtsic support or mechanical heart assistance due to the increased risk of mortality in this patient population. The safety and effectiveness of MitraClip™ in these patients has not been evaluated.
• Patients with a rotated heart due to prior cardiac surgery in whom the System is used may have a potential risk of experiencing adverse events such as atrial perforation, cardiac tamponade, tissue damage, and embolism which may be avoided with preoperative evaluation and proper device usage.
• For the Steerable Guide Catheter and Delivery Catheter only:
  • The Guide catheter: the distal 6.5 cm of the Steerable Guide Catheter with the exception of the distal soft tip, is coated with a hydrophilic coating.
  • The Delivery Catheter: coated with a hydrophilic coating for a length of approximately 131 cm.
• Failure to prepare the device as stated in these instructions and failure to handle the device within care could lead to additional intervention or serious adverse event.
• The Clip Delivery System is provided sterile and designed for single use only. Cleaning, re-sterilization and / or re-use may result in infections, malfunction of the device and other serious injury or death.
• Note the product “Use by” date specified on the package.
• Inspect all product prior to use. Do not use if the package is open or damaged, or if product is damaged.

PRECAUTIONS
• Prohibitive Risk Primary (or degenerative) Mitral Regurgitation
  • Prohibitive risk is determined by the clinical judgment of a heart team, including a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, due to the presence of one or more of the following documented surgical risk factors:
    • 30-day STS predicted operative mortality risk score of
      • ≥ 8% for patients deemed likely to undergo mitral valve replacement or
      • ≥ 6% for patients deemed likely to undergo mitral valve repair
    • Porcelain aorta or extensively calcified ascending aorta.
  • Frailty (assessed by in-person cardiac surgeon consultation)
  • Hostile chest
  • Severe liver disease / cirrhosis (MELD Score ≥ 15)
  • Severe pulmonary hypertension (systolic pulmonary artery pressure ≥ 2/3 systemic pressure)
  • Unusual extenuating circumstance, such as right ventricular dysfunction with severe tricuspid regurgitation, chemotherapy for malignancy, major bleeding diathesis, immobility, AIDS, severe dementia, high risk of aspiration, internal mammary artery (IMA) at high risk of injury, etc.
• Evaluate data regarding safety or effectiveness is not available for prohibitive risk primary patients with an LVEF < 20% or an LVESD > 60 mm. MitraClip™ should be used only when criteria for clip suitability for primary have been met.
• The heart team should include a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease and may also include appropriate physicians to assess the adequacy of heart failure treatment and valvar anatomy.
• Secondary Mitral Regurgitation
  • Evaluable data regarding safety or effectiveness is not available for secondary MR patients with an LVEF < 20% or an LVESD > 70 mm.
• The multidisciplinary heart team should be experienced in the evaluation and treatment of heart failure and mitral valve disease and determine that symptoms and MR severity persist despite maximally tolerated GDMT.

POTENTIAL COMPLICATIONS AND ADVERSE EVENTS
The following ANTICIPATED EVENTS have been identified as possible complications of the MitraClip™ G4 procedure.
• Death; Allergic reactions or hypersensitivity to latex, contrast agent, anaesthesia, device materials (nickel / titanium, cobalt, chromium, polyester), and drug reactions to anticoagulation, or antplatelet drugs;
• Vascular access complications which may require transfusion or vessel repair including: wound dehiscence, catheter site reactions, Bleeding (including ecchymosis, oozing, hematom, hemorrhage, retroperitoneal hemorrhage), Arteriovenous fistula, pseudoaneurysm, aneurysm, dissection, perforation / rupture, vascular occlusion, Emboli (air thrombotic material, implant, device component), Peripheral Nerve Injury;
• Lymphatic complications; Pericardial complications which may require additional intervention, including: Pericardial effusion, Cardiac tamponade, Pericarditis; Cardiac complications which may require additional interventions or emergency cardiac surgery, including: Cardiac perforation, Atrial septal defect; Mitral valve complications, which may complicate or prevent later surgical repair, including: Chordial entanglement / rupture, Single Leaflet Device Attachment (SLDA), Thrombosis, Dislodgement of previously implanted devices, Tissue damage, Mitral valve stenosis, Persistent or residual mitral regurgitation, Endocarditis; Cardiac arrhythmias (including conduction disorders, atrial arrhythmias, ventricular arrhythmias); Cardiac ischemic conditions (including myocardial infarction, myocardial ischemia, and unstable / stable angina); Venous thromboembolism (including deep vein thrombosis, pulmonary embolism, post procedure pulmonary embolism); Stroke / Cerebrovascular accident (CVA) and Transient Ischemic Attack (TIA); System organ failure: Cardio-respiratory arrest, Worsening heart failure, Pulmonary congestion, Respiratory dysfunction / failure / atelectasis, Renal insufficiency or failure, Shock (including cardiogenic and anaphylactic); Blood cell disorders (including coagulopathy, hemolysis, and Heparin Induced Thrombocytopenia (HIT)); Hypotension / hypotension; Infection including: Urinary Tract Infection (UTI), Pneumonia, Septicemia, Nausea / vomitting; Chest pain; Dyspnea; Edema; Fever or hyperthermia; Pain; Fluoroscopy, Transesophageal echocardiogram (TEE) and Transesophageal echocardiogram (TTE) – related complications; Skin injury or tissue changes due to exposure to ionizing radiation, Esophageal irritation, Esophageal perforation, Gastrointestinal bleeding.

CAUTION: This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at vascular.efius.abbott or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Photo on file at Abbott.

Abbott
3200 Lakeside Dr, Santa Clara, CA 95054 USA, Tel: 1.800.227.9902
™ Indicates a trademark of the Abbott Group of Companies.
www.structuralheart.abbott
©2021 Abbott. All rights reserved. MAT-2106017 v1.0 | Item approved for U.S. use only.